

PROSTEN HEALTH HOLDINGS LIMITED

(formerly known as Prosten Technology Holdings Limited) (Incorporated in the Cayman Islands with limited liability)

長 達健康 控股有限公司* (前稱為長達科技控股有限公司) (於開曼群島註冊成立之有限公司) Stock Code 股份代號: 8026

LOOK BEYOND TODAY

2016 INTERIM REPORT 中期業績報告 CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET ("GEM") OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "EXCHANGE")

GEM has been positioned as a market designed to accommodate companies to which a higher investment risk may be attached than other companies listed on the Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities trade on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors (the "Directors") of Prosten Health Holdings Limited (the "Company") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Exchange (the "GEM Listing Rules") for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this report misleading. 香港聯合交易所有限公司(「聯交所」) 創業板(「創業板」)之特色

創業板之定位,乃為相比起其他在聯 交所上市之公司帶有較高投資風險之 公司提供一個上市之市場。有意投資 之人士應了解投資於該等公司之潛在 風險,並應經過審慎周詳之考慮後方 作出投資決定。創業板之較高風險及 其他特色表示創業板較適合專業及其 他經驗豐富之投資者。

由於創業板上市公司新興之性質所 然,在創業板買賣之證券可能會較於 主板買賣之證券承受較大之市場波動 風險,同時無法保證在創業板買賣之 證券會有高流通量之市場。

香港交易及結算所有限公司及聯交所 對本報告之內容概不負責,對其準確 性或完整性亦不發表任何聲明,並明 確表示概不就因本報告全部或任何部 分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。

本報告乃遵照聯交所《創業板證券上市 規則》(「創業板上市規則」) 之規定而提 供有關長達健康控股有限公司(「本公 司」) 之資料,本公司董事(「董事」) 願 就本報告共同及個別承擔全部責任。 董事在作出一切合理查詢後確認,就 彼等所知及所信,本報告所載資料在 各重大方面均屬準確及完整,且並無 誤導或欺騙成分;及本報告並無遺漏 任何事項,致使本報告內任何聲明或 本報告產生誤導。

01

HIGHLIGHTS

Revenue of the Group for the six months ended 30 September 2016 amounted to approximately HK\$8.2 million, representing an increase of approximately HK\$4.0 million as compared to the corresponding period of the previous financial year.

- The Group's gross profit for the six months ended 30 September 2016 was approximately HK\$2.9 million, decreased by approximately HK\$0.6 million as compared with the same period of the last financial year.
- Loss attributable to ordinary shareholders of the Company for the six months ended 30 September 2016 amounted to approximately HK\$9.3 million, which represented an increase in loss of approximately HK\$0.7 million as compared with the same period of the last financial year.
- The Board does not recommend the payment of any interim dividend for the six months ended 30 September 2016.

- 本集團截至二零一六年九月 三十日止六個月之收益為約 8,200,000港元,較上一個財 政年度同期增加約4,000,000 港元。
- 本集團截至二零一六年九月 三十日止六個月之毛利為約 2,900,000港元,較上一個財 政年度同期減少約600,000港 元。
- 截至二零一六年九月三十日止 六個月,本公司普通股股東應 佔虧損為約9,300,000港元, 較上一個財政年度同期虧損增 加約700,000港元。
- 董事會不建議就截至二零一六 年九月三十日止六個月派發任 何中期股息。

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months and three months ended 30 September 2016

The board of Directors (the "Board") of the Company is pleased to announce the unaudited consolidated results of the Company and its subsidiaries (the "Group") for the six months and three months ended 30 September 2016 together with the unaudited comparative figures for the corresponding periods in 2015 as follows:

簡明綜合損益及其他全面收益表

截至二零一六年九月三十日止六個月 及三個月

本公司董事會(「董事會」)欣然宣佈, 本公司及其附屬公司(「本集團」)截至 二零一六年九月三十日止六個月及三 個月之未經審核綜合業績,連同二零 一五年同期之未經審核比較數字如下:

			30 Sep 截至九月三 2016	ths ended otember 十日止六個月 2015	Three mon 30 Sep 截至九月三十 2016	tember 十日止三個月 2015
		Notes 附註	二零一六年 HK\$'000 千港元 (Unaudited) (未經審核)	二零一五年 HK\$'000 千港元 (Unaudited) (未經審核)	二零一六年 HK\$'000 千港元 (Unaudited) (未經審核)	二零一五年 HK\$'000 千港元 (Unaudited) (未經審核)
Revenue Cost of sales	收益 銷售成本	4	8,215 (5,357)	4,235 (738)	3,837 (2,325)	1,986 (382)
Gross profit	毛利		2,858	3,497	1,512	1,604
Other income and gains Selling expenses Administrative expenses Other expenses Finance costs	其他收入及收益 銷售開支 行政開支 其他開支 財務費用		195 (1,536) (10,706) (67)	412 (1,546) (10,759) (229) (10)	4 (911) (5,961) (66)	398 (617) (4,772) (2)
Loss before tax	除税前虧損	5	(9,256)	(8,635)	(5,422)	(3,389)
Income tax expense	所得税開支	6	(33)	_	_	- 4
Loss attributable to ordinary shareholders of the Company	本公司普通股股東 應佔虧損		(9,289)	(8,635)	(5,422)	(3,389)
Other comprehensive income/(expense):	其他全面 					
Item that may be reclassified subsequently to profit or loss:	其後可能重新分類至 損益之項目:					
Exchange differences on translation of foreign operations	換算海外業務 之匯兑差額		(659)	332	(26)	332
Total comprehensive expense attributable to ordinary shareholders of the Company	本公司普通股 股東應佔 全面開支總額		(9,948)	(8,303)	(5,448)	(3,057)
Loss per share Basic	每股虧損 基本	7	(HK0.8 cents)	(HK1.0 cents)	(HK0.5 cents)	(HK0.4 cents)
			(0.8港仙)	(1.0港仙)	(0.5港仙)	(0.4港仙)
Diluted	攤薄		(HK0.8 cents) (0.8港仙)	(HK1.0 cents) (1.0港仙)	(HK0.5 cents) (0.5港仙)	(HK0.4 cents) (0.4港仙)

長達健康控股有限公司 二零一六年中期業績報告

CONDENSED CONSOLIDATED STATEMENT OF 简明綜合財務狀況表

FINANCIAL POSITION

As at 30 September 2016

於二零一六年九月三十日

		3 Notes 附註	0 September 2016 二零一六年 九月三十日 HK\$'000 千港元 (Unaudited) (未經審核)	31 March 2016 二零一六年 三月三十一日 HK\$'000 千港元 (Audited) (經審核)
NON-CURRENT ASSETS	非流動資產			
Property, plant and equipment	物業、廠房及設備	8	7,504	2,067
Long-term prepaid rentals	長期預付租金	9	952	—
Deposits	訂金		77	46
Available-for-sale financial assets	可供出售金融資產		22,179	22,179
Goodwill	商譽		5,092	3,908
Total non-current assets	非流動資產總額		35,804	28,200
CURRENT ASSETS	流動資產			
Inventories	存貨		13,435	15,266
Current portion of long-term	長期預付租金			
prepaid rentals	之流動部分	9	80	<u> </u>
Trade receivables	應收賬款	10	25,566	26,862
Prepayments, deposits	預付款項、訂金及			
and other receivables	其他應收款項		8,192	4,130
Financial asset at fair value	按公平價值列賬及在損益	賬		
through profit or loss	處理之金融資產	11	1,099	-
Cash and cash equivalents	現金及現金等值物	12	15,533	28,761
Total current assets	流動資產總額		63,905	75,019
CURRENT LIABILITIES	流動負債			
Trade payables	應付賬款	13	3,623	2,703
Other payables and accruals	其他應付款項及			
	應計款項		14,420	8,336
Due to non-executive Directors	應付非執行董事之款項		4,966	5,425
Due to an ultimate	應付最終控股公司之			
holding company	款項		142	142
Due to de-consolidated	應付取消綜合入賬			
subsidiaries	附屬公司之款項		15,300	15,300
Tax payable	應付税項		71	178
Total current liabilities	流動負債總額		38,522	32,084

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED)

簡明綜合財務狀況表 (續)

As at 30 September 2016

於二零一六年九月三十日

		3	0 September 2016 二零一六年	31 March 2016 二零一六年
		Note 附註	 九月三十日 HK\$'000 千港元 (Unaudited) (未經審核)	_ ~
NET CURRENT ASSETS	流動資產淨值		25,383	42,935
TOTAL ASSETS LESS CURRENT LIABILITIES	資產總額減流動負債		61,187	71,135
NON-CURRENT LIABILITY Deferred tax liability	非流動負債 遞延税項負債		181	181
NET ASSETS	資產淨值		61,006	70,954
Equity attributable to ordinary shareholders of the Company	本公司普通股股東 應佔權益			
Issued capital Reserves	已發行股本 儲備	14	109,536 (48,530)	109,536 (38,582)
TOTAL EQUITY	權益總額		61,006	70,954

CONDENSED CONSOLIDATED STATEMENT OF 简明綜合權益變動表 **CHANGES IN EQUITY**

For the six months ended 30 September 2016

截至二零一六年九月三十日止六個月

		Attributable to ordinary shareholders of the Company 本公司普通股股東應佔								
		Share capital 股本 HK\$'000 千港元	Share premium account 股份 溢價賬 HK\$'000 千港元	Statutory reserve fund 法定 儲備基金 HK\$'000 干港元 (note a) (附註a)	Available- for-sale financial assets equity reserve 可供出資產 權益整 整 物 (note b) (附註b)	Foreign currency translation reserve 外幣 匯兑儲備 HK\$'000 干港元 (note c) (附註c)	Share option A reserve 購股權 儲備 HK\$'000 千港元	ccumulated losses 累計 虧損 HK\$'000 千港元	Reserves sub-total 儲備 小計 HK\$'000 千港元	Total equity 權益 總計 HK\$'000 千港元
As at 1 April 2016 (audited)	於二零一六年四月一日 (經審核)	109,536	455,438	3,349	6,760	14,766	316	(519,211)	(38,582)	70,954
Loss for the period (unaudited) Other comprehensive expense for the period (unaudited): Exchange differences on translation of foreign operations (unaudited)	期內虧損(未經審核) 第內其他全面開支 (未經審核): 換與為外奏務之匯兑差額 (未經審核)		-	_	-	(659)	-	(9,289)	(9,289) (659)	(9,289) (659)
Total comprehensive expense for the period (unaudited)	期內全面開支總額 (未經審核)	_	_	-	-	(659)	-	(9,289)	(9,948)	(9,948)
As at 30 September 2016 (unaudited)	於二零一六年九月三十日 (未經審核)	109,536	455,438	3,349	6,760	14,107	316	(528,500)	(48,530)	61,006

CONDENSED CONSOLIDATED STATEMENT OF 簡明綜合權益變動表(續) CHANGES IN EQUITY (CONTINUED)

For the six months ended 30 September 2015

截至二零一五年九月三十日止六個月

		Attributable to ordinary shareholders of the Company 本公司普通股股東應佔								
		Share capital 股本 HK\$'000 千港元	Share premium account 股份 溢價賬 HK\$'000 千港元	Statutory reserve fund 法定 儲備基金 HK\$*000 千港元 (note a) (附註a)	Foreign currency translation reserve 外幣 匯兑儲備 HKS'000 千港元 (note c) (附註c)	Share option reserve 購股權 儲備 HK\$'000 千港元	Accumulated losses 累計 虧損 HKS'000 千港元	Reserves sub-total 儲備 小計 HK\$'000 千港元	Total equity 權益 總計 HK\$'000 千港元	
As at 1 April 2015 (audited)	於二零一五年四月一日 (經審核)	79,610	378,628	3,349	14,787	611	(487,852)	(90,477)	(10,867)	
Loss for the period (unaudited) Other comprehensive income/(expense) for the period (unaudited): Exchange differences on transletion of foreign	期內虧損(未經審核) 期內其他全面 收入/(開支)(未經審核): 換算海外業務之匯兑差額 (未經審核)	-	-		-	-	(8,635)	(8,635)	(8,635)	
translation of foreign operations (unaudited)	(木ピ奋仮)	_	_	_	332	_	_	332	332	
Total comprehensive income/(expense) for the period (unaudited)	期內全面收益/(開支)總額 (未經審核)				332	_	(8,635)	(8,303)	(8,303)	
Equity-settled share option arrangements (unaudited) Exercise of share options	以權益結算之購股權安排 (未經審核) 行使購股權	-	_	-	-	79	_	79	79	
(unaudited)	(未經審核)	314	704	-	-	(401)	-	303	617	
Placement of new shares (unaudited) Expenses on issue of new	配售新股 (未經審核) 發行新股之開支	13,627	44,969	-	-	-	-	44,969	58,596	
shares (unaudited)	(未經審核)	-	(1,361)	-	-	-	-	(1,361)	(1,361)	
As at 30 September 2015 (unaudited)	於二零一五年九月三十日 (未經審核)	93,551	422,940	3,349	15,119	289	(496,487)	(54,790)	38,761	

Notes:

(a) Statutory reserve fund

Pursuant to the relevant laws and regulations for business enterprises in the People's Republic of China (the "PRC"), a portion of the profits of the entities which are registered in the PRC has been transferred to the statutory reserve fund which is restricted as to use. When the balance of such reserve fund reaches 50% of the capital of that entity, any further appropriation is optional. The statutory reserve fund can be utilised, upon approval of the relevant authority, to offset prior years' losses or to increase capital. However, the balance of the statutory reserve fund must be maintained at least 25% of capital after such usage.

(b) Available-for-sale financial assets equity reserve

Available-for-sale financial assets equity reserve relates to the cumulative gains or losses arising on the change in fair value of available-for-sale financial assets that have been recognised in other comprehensive income, net of amounts reclassified to profit or loss when those financial assets are disposed or impaired.

(c) Foreign currency translation reserve

Foreign currency translation reserve represents exchange differences relating to the translation of the net assets of the Group's foreign operations from their functional currencies to the Group's presentation currency (i.e. Hong Kong dollar) are recognised directly in other comprehensive income and accumulated in the foreign currency translation reserve. Such exchange differences accumulated in the foreign currency translation reserve are reclassified to profit or loss on the disposal or de-consolidation the foreign operations. 附註:

(a) 法定儲備基金

根據中華人民共和國(「中國」)的相 關企業法律及條例,於中國註冊之 實體之部分溢利已轉撥至有限定用 途之法定儲備基金。當該等儲備基 金結餘達該實體資本之50%時,可 選擇是否作出進一步劃撥。法定 備基金僅在獲得相關部門批准後方 可動用,以抵銷以往年度之虧損或 增資。然而,運用法定儲備基金後 之結餘須至少維持在資本之25%。

(b) 可供出售金融資產權益儲備

可供出售金融資產權益儲備乃與因 可供出售金融資產之公平價值變動 (已於其他全面收益確認)而產生之 累計收益或虧損有關,當中已扣減 於該等金融資產出售或減值時重新 分類至損益之金額。

(c) 外幣匯兑儲備

外幣匯兑儲備指有關本集團海外業 務之資產淨值由其功能貨幣換算為 本集團之呈列貨幣(即港元)產生之 匯兑差額,直接於其他全面收益中 確認及於外幣匯兑儲備中累計。該 等於外幣匯兑儲備累計之匯兑差額 於出售或取消海外業務綜合入賬時 重新分類至損益賬內。

CONDENSED CONSOLIDATED STATEMENT OF 簡明綜合現金流量表 CASH FLOWS

For the six months ended 30 September 2016 截至二零一六年九月三十日止六個月

		Six months ended 30 September 截至九月三十日止六個月		
		2016 二零一六年 HK\$'000 千港元 (Unaudited) (未經審核)	2015 二零一五年 HK\$'000 千港元 (Unaudited) (未經審核)	
Net cash flows used in operating activities	經營業務所用之 現金流量淨額	(2,286)	(6,631)	
Net cash flows used in investing activities	投資業務所用之 現金流量淨額	(10,283)	(3,338)	
Net cash flows generated from financing activities	融資業務所產生之 現金流量淨額	_	60,583	
Net (decrease)/increase in cash and cash equivalents	現金及現金等值物(減少)/ 增加淨額	(12,569)	50,614	
Cash and cash equivalents at beginning of period	期初之現金及現金等值物	28,761	1,778	
Effect of foreign exchange rate changes, net	匯率變動之影響淨額	(659)	332	
Cash and cash equivalents at end of period	期末之現金及現金等值物	15,533	52,724	
Analysis of cash and cash equivalents	現金及現金等值物分析			
Cash and bank balances	現金及銀行結餘	15,533	52,724	

Notes:

1. ORGANISATION AND PRINCIPAL ACTIVITY

The Company is a limited liability company incorporated in the Cayman Islands. The address of its registered office is Century Yard, Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, the Cayman Islands. The address of its principal place of business in Hong Kong is Unit 905, Star House, 3 Salisbury Road, Tsim Sha Tsui, Kowloon, Hong Kong. The Company's shares are listed on the GEM.

With effect from 21 October 2016, the name of the Company was changed from Prosten Technology Holdings Limited to Prosten Health Holdings Limited.

2. BASIS OF PREPARATION

The Group's unaudited consolidated results have been prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") (which include all individual Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards ("HKAS") and Interpretations) issued by the Hong Kong Institute of Certified Public Accountants and accounting principles generally accepted in Hong Kong. In addition, the unaudited consolidated results include applicable disclosures required by the GEM Listing Rules. The measurement basis used in the preparation of the unaudited consolidated results is the historical cost convention, except for the available-forsale financial assets and financial assets at fair value through profit or loss which have been measured at fair value. These unaudited consolidated results are presented in Hong Kong dollar, which is also the functional currency of the Company and all values are rounded to the nearest thousand except when otherwise indicated. The Group's major subsidiaries are operated in the PRC with Renminbi as their functional currency.

The accounting policies applied in the preparation of the unaudited consolidated results are consistent with those adopted in the preparation of the annual consolidated financial statements of the Group for the year ended 31 March 2016, except that the Group has adopted a number of new or revised HKFRSs, which are newly effective for the period under review. The adoption of these new or revised HKFRSs had no significant effect on the financial results of the current periods. Accordingly, no change in significant accounting policies and no prior period adjustment is required. 附註:

1. 組織及主要業務

本公司為一間於開曼群島註冊成 立之有限公司。其註冊辦事處地 址為Century Yard, Cricket Square, Hutchins Drive, PO. Box 2681, Grand Cayman KY1-1111, the Cayman Islands。其香港主要營業地點地址 為香港九龍尖沙咀梳士巴利道3號星 光行905室。本公司之股份於創業板 上市。

自二零一六年十月二十一日起,本 公司之名稱由長達科技控股有限公 司更改為長達健康控股有限公司。

2. 編製基準

本集團之未經審核綜合業績乃根據 香港會計師公會頒佈之香港財務報 告準則(「香港財務報告準則」)(包 括所有個別香港財務報告準則、香 港會計準則(「香港會計準則」)及詮 釋) 及香港普遍採納之會計原則而 編製。此外,未經審核綜合業績包 括創業板上市規則所規定之適用披 露。用於編製此等未經審核綜合業 績之計量基準乃歷史成本慣例,惟 可供出售金融資產以及按公平價值 列賬及在損益賬處理之金融資產以 公平價值列賬。除另有指明外,此 等未經審核綜合業績以港元(亦為本 公司之功能貨幣)呈列,所有金額均 調整至最接近千位數。本集團之主 要附屬公司乃於中國經營業務,其 功能貨幣為人民幣。

編製未經審核綜合業績採用之會計 政策,乃與編製本集團截至二年 一六年三月三十一日止年度之全年 综合財務報表所採納者貫徹一致, 惟本集團採納多項於回顧期內新生 製納。採納該等新訂或經修訂香港財務報告準 則。採納該等新訂或經修訂香港財 務報告準則對。因此,毋須對重大影響。因此,毋須對重大影響。因此,毋須對重大影響。 計政策作出變更及毋須作出往期調 整。 The Group has not applied or early adopted the new or revised HKFRSs (including their consequential amendments) which are relevant to the Group that have been issued but are not yet effective in the preparation of these unaudited consolidated results. The Group is in the process of assessing the impact of these new or revised HKFRSs upon initial application but is not yet in a position to state whether they would have any significant impact on the Group's results of operation and financial position. It is anticipated that all of the pronouncements will be adopted in the Group's accounting policies in the accounting period when they first become effective.

The unaudited consolidated results have been reviewed by the audit committee of the Company ("Audit Committee") and the auditors.

3. OPERATING SEGMENT INFORMATION

The Group's operating activities are currently attributable to four operating segments focusing on the wireless valueadded services, trading and retailing of jewelry, lending business and pharmaceutical and healthcare products business (continuing operation). These operating segments have been identified on the basis of internal management reports prepared in accordance with accounting policies conformed to HKFRSs, that are regularly reviewed by the executive Directors (the "Executive Directors") (being the chief operating decision maker of the Company). The Executive Directors review the Group's internal reporting in order to assess performance and allocate resources. The details of operating and reportable segments of the Group are as follows:

- Wireless valued-added services
- Trading and retailing of jewelry
- Lending business
- Pharmaceutical and healthcare products

本集團並無於編製此等未經審核綜 合業績時應用或提早採納與本集團 相關的已經頒佈但尚未生效的新訂 或經修訂香港財務報告準則(包括其 後續修訂)。本集團正在評估首次採 用此時之影響,惟仍未能確定彼等 起況構成任何重大影響。預期所約 額依之準則將於其首次生效時之 貢 前間納入本集團之會計政策。

未經審核綜合業績已由本公司之審 核委員會(「審核委員會」)及核數師 審閱。

3. 經營分部資料

本集團之經營業務目前歸屬於四個 專注於無線增值服務,珠寶買賣及 實零售、借貸業務以及募業及健康資 。該等經營分部乃基於遵循香港 財務報告準則之會計政策而編製之 內部管理報告予以識別,並由執行 董鄉(「執行董事」,為本公司之主等 經營決策者)定期審閱。執行董事 及配資源。本集團之經營及可申報 分部詳情如下:

- 無線增值服務
- 珠寶買賣及零售
 - 借貸業務
- 藥業及健康護理產品

The pharmaceutical and healthcare products business was introduced to the Group in the first quarter of the year ending 31 March 2017. The following is an analysis of the Group's revenue and results by operating segments: 本集團於截至二零一七年三月 三十一日止年度第一季度開始從事 藥業及健康護理產品業務。按經營 分部劃分之本集團收益及業績分析 如下:

For the six months ended 30 September 2016 截至二零一六年 九月三十日止六個月		Wireless valued-added services 無線增值服務 HK\$'000	Trading and retailing of jewelry 珠寶買賣 及零售 HK\$*000	P Lending business 借貸業務 HK\$'000	harmaceutical and healthcare products 藥業及 健康護理產品 HK\$'000	Consolidation 合計 HK\$'000
		千港元 (Unaudited) (未經審核)	千港元 (Unaudited) (未經審核)	千港元 (Unaudited) (未經審核)	千港元 (Unaudited) (未經審核)	千港元 (Unaudited) (未經審核)
REVENUE	收益					
External sales	外部銷售	-	2,837	1,743	3,635	8,215
RESULTS	業績					
Segment results profit/(loss)	分部業績溢利/(虧損)	(1,002)	(1,095)	1,004	(1,068)	(2,161)
Unallocated expenses	未分配開支					(7,095)
Loss before taxation	除税前虧損					(9,256)

For the six months ended 30 September 2015, the Group had one single operating segment as it was principally engaged in the wireless value-added services and related business which was the basis to allocate resources and assess performance. Hence, no business segment information was presented for the six months ended 30 September 2015. As most of the Group's customers and operations were located in the PRC, no geographical information was presented for the six months period ended 30 September 2016 and 2015.

Segment profit/loss represents the profit/loss earned/ suffered by each segment without allocation of central administration costs, certain other income and gains and other expenses. This is the measure reported to the Executive Directors for the purposes of resource allocation and performance assessment. 截至二零一五年九月三十日止六個 月,由於本集團主要從事無線增值 服務及相關業務,並以此作為分配 資源及評估表現之基準,故本集團 僅擁有一個經營分部。因此,本集 團並無呈列截至二零一五年九月 三十日止六個月之業務分部資料。 由於本集團之大部分客戶及業務均 吃於中國,故並無呈列截至二六年及二零一六年九月三十日止 六個月期間之地區資料。

分部溢利/虧損指各分部所賺取之 溢利/產生之虧損,當中並未分配 中央行政成本、若干其他收入及收 益以及其他開支。此乃為分配資源 及評估表現而向執行董事匯報之基 準。 The following is an analysis of the Group's assets and liabilities by operating segment:

按經營分部劃分之本集團資產及負 債分析如下:

		30 September 2016 二零一六年 九月三十日 HK\$'000 千港元 (Unaudited) (未經審核)	31 March 2016 二零一六年 三月三十一日 HK\$'000 千港元 (Audited) (經審核)
SEGMENT ASSETS	分部資產		
Wireless valued-added services	無線增值服務	4,009	2,061
Trading and retailing of jewelry	珠寶買賣及零售	14,767	32,041
Lending business	借貸業務	37,509	29,098
Pharmaceutical and healthcare products	藥業及健康護理產品	40,445	_
Unallocated assets	未分配資產	2,979	40,019
		99,709	103,219
SEGMENT LIABILITIES	分部負債		
Wireless valued-added services	無線增值服務	29,089	30,316
Trading and retailing of jewelry	珠寶買賣及零售	1,066	881
Lending business	借貸業務	149	249
Pharmaceutical and healthcare products	藥業及健康護理產品	5,633	_
Unallocated liabilities	未分配負債	2,766	819
		38,703	32,265

For the purposes of monitoring segment performances and allocating resources between segments:

- all assets are allocated to operating segments other than certain prepayments and bank balances and cash held by the respective head offices from continuing operation was allocated to the above components segment; and
- all liabilities are allocated to operating segments other than liabilities of the respective head offices from continuing operation, deferred taxation, and taxation payable from each segment.

為監察分部表現及於各分部間分配 資源:

- 除各持續經營業務的總部持 有之若干預付款項及銀行結 餘及現金分配至上述分部 外,所有資產均分配至經營 分部;及
- 除各持續經營業務的總部之 負債、各分部之遞延税項及 應付税項外,所有負債均分 配至經營分部。

Information about major customers

During the six months ended 30 September 2016, revenue of approximately HK\$2,568,000 (2015: HK\$4,235,000), which represents approximately 31% (2015: 100%) of the Group's total sales, was derived from goods sold (2015: services rendered) to two customers (2015: one customer). During the three months ended 30 September 2016, revenue of approximately HK\$1,058,000 (2015: HK\$1,986,000), which represents approximately 28% (2015: 100%) of the Group's sales, was derived from goods sold (2015: services rendered) to one customer. Except as disclosed above, no other single customer contributed 10% or more to the Group's revenue for both the six months and three months ended 30 September 2016 and 2015.

4. REVENUE

Revenue represents the invoiced value of goods sold and services rendered during the periods.

5. LOSS BEFORE TAX

The Group's loss before tax is arrived at after charging/ (crediting):

有關主要客戶之資料

於截至二零一六年九月三十日止六 個月,約2,568,000港元(二零一五 年:4,235,000港元)之收益(佔本 集團總銷售額約31%(二零一五年: 100%)) 乃源自向兩位客戶(二零 一五年:一位客戶)銷售之產品(二 零一五年:提供之服務)。於截至 二零一六年九月三十日止三個月, 約1,058,000港元(二零一五年: 1,986,000港元)之收益(佔本集團銷 售額約28%(二零一五年:100%)) 乃源自向一位客戶銷售之產品 (二零 一五年:提供之服務)。除上述披露 者外,概無其他單一客戶於本集團 截至二零一六年及二零一五年九月 三十日止六個月及三個月之收益中 佔10%或以上之比重。

4. 收益

收益指期內產品銷售及所提供服務 之發票值。

5. 除税前虧損

本集團之除税前虧損經扣除/(計入)下列各項後達致:

		Six months ended		Three months ended		
		30 September		30 Sep	tember	
		截至九月三十	十日止六個月	截至九月三一	十日止三個月	
		2016	2015	2016	2015	
		二零一六年	二零一五年	二零一六年	二零一五年	
		HK\$'000	HK\$'000	HK\$'000	HK\$'000	
		千港元	千港元	千港元	千港元	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
		(未經審核)	(未經審核)	(未經審核)	(未經審核)	
Depreciation	折舊	507	443	148	220	
Minimum lease payments under operating leases in respect of land and	土地及樓宇之 經營租賃最低租賃 付款					
buildings		2,543	837	1,200	404	
Employee benefits expense	僱員福利開支	4,154	6,061	1,852	2,661	
Investment loss/(income)	投資虧損/(收入)	(174)	(17)	22	(9)	

6. INCOME TAX EXPENSE

Hong Kong profits tax is calculated at 16.5% of the estimated assessable profit for the six months ended 30 September 2016. Hong Kong profits tax has not been provided as the Group did not generate any assessable profits arising in Hong Kong for the six months ended 30 September 2015. Taxes on profits assessable elsewhere have been calculated at the rates of tax prevailing in the countries or jurisdictions in which the Group operates.

6. 所得税開支

截至二零一六年九月三十日止六個 月,香港利得税乃按估計應課税溢 利之16.5%計算。由於本集團於截至 二零一五年九月三十日止六個月內 並無錄得任何於香港產生之應課税 溢利,故並區之應課税溢利乃根據 本集團經營業務所在之國家或司法 權區當地之現行税率計算税項。

		Six months ended 30 September 截至九月三十日止六個月		ended 30	months September 十日止三個月
		2016 二零一六年 HK\$'000 千港元 (Unaudited) (未經審核)	2015 二零一五年 HK\$'000 千港元 (Unaudited) (未經審核)	2016 二零一六年 HK\$'000 千港元 (Unaudited) (未經審核)	2015 二零一五年 HK\$'000 千港元 (Unaudited) (未經審核)
Current — Hong Kong: Charge for the period	即期 — 香港: 期內支出	33	_	-	_
Total tax charged for the period	期內税項支出總額	33	_	_	_

7. LOSS PER SHARE

The calculation of basic loss per share amount for the six months ended 30 September 2016 is based on the unaudited loss for the period attributable to ordinary shareholders of the Company of approximately HK\$9,289,000 (2015: HK\$8,635,000) and the number of ordinary shares of approximately 1,095,361,000 in issue for the six months ended 30 September 2016 (2015: weighted average of 828,634,000).

The calculation of basic loss per share amount for the three months ended 30 September 2016 is based on the unaudited loss for the period attributable to ordinary shareholders of the Company of approximately HK\$5,422,000 (2015: HK\$3,389,000) and the number of ordinary shares of approximately 1,095,361,000 in issue for the three months ended 30 September 2016 (2015: weighted average of 859,942,000).

As there were no dilutive potential equity shares in existence as at 30 September 2016 and 2015, the basic and diluted loss per share were the same for the periods.

7. 每股虧損

截至二零一六年九月三十日止六個 月之每股基本虧損金額乃根據未經 審核之本公司普通股股東應佔期內 虧損約9,289,000港元(二零一五年: 8,635,000港元)及截至二零一六年 九月三十日止六個月之已發行普通 股數約1,095,361,000股(二零一五 年:加權平均數828,634,000股)計 算。

截至二零一六年九月三十日止三個 月之每股基本虧損金額乃根據未經 審核之本公司普通股股東應佔期內 虧損約5,422,000港元(二零一五年: 3,389,000港元),以及截至二零一元 年九月三十日止三個月之已發行普 通股數約1,095,361,000股(二零一五 年:加權平均數859,942,000股)計 算。

由於於二零一六年及二零一五年九 月三十日並無存在潛在攤薄權益股 份,期內之每股基本及攤薄虧損相 同。

8. PROPERTY, PLANT AND EQUIPMENT

8. 物業[、]廠房及設備

The movements of property, plant and equipment of the Group were as follows:

本集團之物業	•	廠房及設備變動
如下:		

		30 September 2016 二零一六年 九月三十日 HK\$'000 千港元 (Unaudited) (未經審核)	31 March 2016 二零一六年 三月三十一日 HK\$'000 干港元 (Audited) (經審核)
Net book value,	賬面淨值・期初/年初		
at beginning of period/year		2,067	2,351
Additions for the period/year	期/年內添置	230	395
Acquisition of subsidiaries	收購附屬公司	5,783	1,637
De-consolidation of subsidiaries	取消附屬公司綜合入賬	_	(1,158)
Disposals for the period/year	期/年內出售	(30)	
Depreciation for the period/year	期/年內折舊	(507)	(1,114)
Exchange realignment	期/年內匯兑調整淨額		
for the period/year, net		(39)	(44)
Net book value,	賬面淨值,期末/年末		
at end of period/year		7,504	2,067

9. LONG-TERM PREPAID RENTALS

This represents the prepayment of long-term rentals for the business on pharmaceutical and healthcare products segment as at the end of the reporting period under operating leases in the PRC. The lease terms is 13 years. The movements of the long-term prepaid rentals are summarised as follows:

9. 長期預付租金

長期預付租金指於報告期末於中國 按經營租賃有關藥業及健康護理產 品分部業務之長期租金預付款項。 租期為13年。長期預付租金之變動 概述如下:

		30 September 2016 二零一六年 九月三十日 HK\$'000 千港元 (Unaudited) (未經審核)	31 March 2016 二零一六年 三月三十一日 HK\$'000 千港元 (Audited) (經審核)
Cost At beginning of period/year Addition during the period/year	成本 於期初/年初 期/年內添置		_
At end of period/year	於期末/年末	1,032	_
Accumulated amortization and impairment loss At beginning of period/year Amortisation for the period/year	累計攤銷 及減值虧損 於期初/年初 期/年內攤銷	Ξ	=
At end of period/year	於期末/年末	_	-
Carrying amount at end of period/year	於期末/年末之賬面值	1,032	<u> </u>
Analysis of long-term prepaid rentals is as follows:	長期預付租金 之分析如下:		
Non-current portion Current portion	非流動部分 流動部分	952 80	1
Carrying amount at end of period/year	於期末/年末之賬面值	1,032	-

		30 September 2016 二零一六年 九月三十日 HK\$'000 千港元 (Unaudited) (未經審核)	31 March 2016 二零一六年 三月三十一日 HK\$'000 千港元 (Audited) (經審核)
Trade receivables, gross	應收賬款總額	1,412	2,275
Impairment allowances	減值撥備	—	(1,491)
Loans receivables	應收貸款	24,154	26,078
Trade receivables, net	應收賬款淨額	25,566	26,862

The Group's trade receivables, which generally have credit terms of one month to six months (31 March 2016; one month to three months) pursuant to the provisions of the relevant contracts, are recognised based on services rendered and money lended and carried at the original invoice amount, and an estimate of impairment of trade receivables is made and deducted when collection of the full amount is no longer probable. At the end of the reporting period, the Group has significant concentration of credit risk as approximately 52% (31 March 2016: 49%) of the balance represented a receivable from a customer with the largest trade receivable balances at the end of the reporting period. The trade receivables balance as at 30 September 2016 contributed by the five largest customers of the six months ended 30 September 2016 was 98% (31 March 2016; 100%). Concentration of credit risk is managed by control over credit term over individual customer. Trade receivables are unsecured and non-interest-bearing.

An aged analysis of the Group's trade receivables, net of impairment allowances, based on the date of invoice, is as follows:

根據有關合約之規定,本集團之應 收賬款一般均有一個月至六個月(二 零一六年三月三十一日:一個月至 三個月) 之信貸期。應收賬款基於 已提供之服務及貸出款項予以確認 及按原始發票金額列賬,並在不 可能收回其全部金額時作出應收賬 款減值估計, 並予以扣除。於報告 期末,本集團存在重大集中信貸風 險,原因為約52%(二零一六年三月 三十一日:49%) 之結餘為於報告期 末最大應收客戶之款項。截至二零 一六年九月三十日止六個月內五大 客戶的期末結餘佔二零一六年九月 三十日之應收賬款結餘之98%(二零 一六年三月三十一日:100%)。本集 團透過控制個別客戶之信貸期管理 集中信貸風險。應收賬款為無抵押 及不計息。

本集團應收賬款(扣除減值撥備)根 據發票日期之賬齡分析如下:

		30 September 2016 二零一六年 九月三十日 HK\$'000 千港元	31 March 2016 二零一六年 三月三十一日 HK\$'000 千港元
		(Unaudited) (未經審核)	(Audited) (經審核)
Within three months	三個月內	25,566	26,862

The Group does not hold any collateral or other credit enhancements over these balances.

本集團並無就該等結餘持有任何抵 押品或作出其他信貸改善措施。

FINANCIAL ASSETS AT FAIR VALUE THROUGH 11. **PROFIT OR LOSS**

11. 按公平價值列賬及在損益賬處 理之金融資產

30 September	31 March
2016	2016
二零一六年	二零一六年
九月三十日	三月三十一日
НК\$'000	HK\$'000
千港元	千港元
(Unaudited)	(Audited)
(未經審核)	(經審核)

Listed securities:	上市證券:		
— Equity securities listed in the PRC,	一於中國上市之權益		
at fair value	證券,按公平價值	1,099	—

At the end of the reporting period, financial assets at fair value through profit or loss are stated at fair value. Fair values of listed securities are determined with reference to quoted market prices.

於報告期末,按公平價值列賬及在 損益賬處理之金融資產按公平價值 列賬。上市證券之公平價值乃經參 考市場報價而釐定。

12. **CASH AND CASH EQUIVALENTS**

現金及現金等值物 12. 30 September 31 March 2016 2016 二零一六年 二零一六年 九月三十日 三月三十一日 HK\$'000 HK\$'000 千港元 千港元 (Unaudited) (Audited) (未經審核) (經審核) Cash and bank balances 現金及銀行結餘 15,433 28,661 Time deposit 定期存款 100 100

Cash at banks earns interest at floating rates based on daily bank deposit rates. Short term time deposits were made for varying periods of between one day and three months depending on the immediate cash requirements of the Group, and earn interest at the respective short term time deposit rates. The deposits at banks are deposited with creditworthy banks with no recent history of default.

银行存款根據每日銀行存款利率釐 定之浮動利率計息。短期定期存款 的週期為期一日至三個月不等,視 乎本集團當時之現金需要而定,並 按有關之短期定期存款利率計息。 於銀行之存款存放於近期並無不良 信貸記錄且信譽良好之銀行。

15,533

28,761

13. TRADE PAYABLES

An aged analysis of the Group's trade payables, based on the month in which the services were rendered/invoice date , is as follows:

13. 應付賬款

本集團應付賬款根據提供服務月份/ 發票日期之賬齡分析如下:

		30 September 2016 二零一六年 九月三十日 HK\$'000 千港元 (Unaudited) (未經審核)	31 March 2016 二零一六年 三月三十一日 HK\$'000 千港元 (Audited) (經審核)
Within three months	三個月內	920	_
Over 1 year	超過一年	2,703	2,703
		3,623	2,703

14. SHARE CAPITAL

14. 股本

		30 Septem 二零一六年: Number of shares 股份數目 '000 千股 (Unauu (未經:	九月三十日 HK\$′000 千港元 Jited)	31 March 二零一六年三 Number of shares 股份數目 '000 千股 (Audit	月三十一日 HK\$'000 千港元 ed)
Authorised: Ordinary shares of HK\$0.10 (31 March 2016: HK\$0.10) each	法定: 每股面值0.10港元之 普通股(二零一六年 三月三十一日: 0.10港元)	2,500,000	<u>第1次</u> 250,000	(紅田)	250,000
Issued and fully paid: Ordinary shares of HK\$0.10 (31 March 2016: HK\$0.10) each	已發行及繳足 : 每股面值0.10港元之 普通股(二零一六年 三月三十一日: 0.10港元)				
At beginning of period/year Exercise of share options Placing of new shares	於期初/年初 行使購股權 配售新股	1,095,361 	109,536 	796,105 3,138 296,118	79,610 314 29,612
At end of period/year	於期末/年末	1,095,361	109,536	1,095,361	109,536

15. **ACQUISITION OF A SUBSIDIARY**

Sino Yao Shang Technology Limited

In May 2016, the Group has entered into an agreement to acquire 100% equity interest in Sino Yao Shang Technology Limited and its subsidiaries at a total consideration of approximately HK\$9,300,000. The acquisition was completed on 30 August 2016. The aggregate consideration of approximately HK\$9,300,000 has been settled by cash.

15. 收購一間附屬公司

中國藥商科技有限公司

本集團於二零一六年五月已訂立一 項協議,以收購中國藥商科技有限 公司及其附屬公司100%股本權益, 總代價約為9,300,000港元。該收購 事項已於二零一六年八月三十日完 成。合共代價約9,300,000港元已以 現金結算。

		Fair value recognised on acquisition 收購時確認之 公平價值 HK\$'000 千港元 (Unaudited) (未經審核)
Net assets acquired: Property, plant and equipment Deposits, prepayments and other receivables Cash and cash equivalents Accruals and other payables	收購之資產淨值: 物業、廠房及設備 訂金、預付款項及其他應 現金及現金等值物 應計款項及其他應付款項	43
Net assets acquired by the Group Goodwill arising on acquisition	本集團收購之資產淨值 收購產生之商譽	8,116 1,184
Total consideration	總代價	9,300
Satisfied by: Cash	按以下方式支付: 現金	9,300
Net cash outflow on acquisition: Consideration paid in cash Less: Cash and cash equivalents	收購產生之現金流出淨額 以現金支付之代價 減:現金及現金等值物	: 9,300 (43)
		9,257
None of the goodwill arising on this acquisit to be deductible for tax purposes.	ion is expected	收購所產生之商譽概不會就税務目 的而遭扣減。
		い 時 中 岡 茶 充 利 井 左 四 へ ヨ み 井 叶

The goodwill arising on the acquisition of Sino Yao Shang Technology Limited and its subsidiaries is attributable to the business development on the segment of pharmaceutical and healthcare products.

收購中國藥商科技有限公司及其附 屬公司產生之商譽歸因於藥業及健 康護理產品分部之業務發展。

The goodwill is allocated to the segment of pharmaceutical and healthcare products.

Impact of acquisition on the results of the Group

Had the acquisition of Sino Yao Shang Technology Limited and its subsidiaries been effected at 1 April 2016, the Group's revenue for the six months period ended 30 September 2016 would have been about HK\$8,215,000 and the consolidated loss for the year would have been about HK\$13,097,000. The pro forma information is for illustrative purposes only and is not necessarily an indication of the revenue and results of operations of the Group that actually would have been achieved had the acquisition been completed in August 2016, nor is it intended to be a projection of future results.

16. COMMITMENTS

16. 承擔

(a)	Operating lease arrangements		(a)	經營租賃安排	
	The Group leases its office properties under operating lease arrangements. Leases for properties are negotiated for terms ranging from one to three years (31 March 2016: one to three years).			賃其辦公室物 賃經磋商後 一至三年(二	望營租賃安排租 刘業。物業之租 有關租賃期為 零一六年三月 至三年) 不等。
	At the end of the reporting period, the Group had total future minimum lease payments under non- cancellable operating leases falling due as follows:			可撤銷經營租	本集團根據不 1
				September 2016 二零一六年 九月三十日 HK\$'000 千港元 Unaudited) (未經審核)	31 March 2016 二零一六年 三月三十一日 HK\$'000 千港元 (Audited) (經審核)
	Land and buildings: 土地及樓宇 : Within one year 一年內 In the second to fifth years, 第二至第五年 inclusive (包括首尾兩年)	H	4,530 10,015	3,457 11,592
				14,545	15,049
(b)	Capital commitments		(b)	資本承擔	
	The Group has no significant capital commitment as at 30 September 2016 and 31 March 2016.				=九月三十日及 =月三十一日, 大資本承擔。

商譽分配至藥業及健康護理產品分 部。

收購對本集團業績之影響

假設收購中國藥商科技有限公司及 其附屬公司於二零一六年四月一日 生效,本集團於截至二零一六年九 月三十日止六個月期間之收益及年 度綜合虧損將分別為約8,215,000港 元及約13,097,000港元。該備考資料 僅供説明用途,未必反映本集團於 假設收購已於二零一六年八月完成 的情況下所實際錄得的收益及經營 業績,亦不擬作為未來業績的預測。

PROSTEN HEALTH HOLDINGS LIMITED Interim Report 2016

17. EVENTS AFTER THE REPORTING PERIOD

Change Company's name

The name of the Company was changed from "Prosten Technology Holdings Limited" to "Prosten Health Holdings Limited". Further details were set out in the Company's announcement dated 18 October 2016.

Extension of loan receivable

On 21 October 2016, the Group entered into the extension agreement with the borrower whereby the final repayment date of the loan in the amount of HK\$6,000,000 was extended for 2 months from 21 October 2016 to 21 December 2016. Further details were set out in the Company's announcement dated 21 October 2016.

Completion of subscription of convertible note

On 31 May 2016, the Company announced the conditional subscription of a convertible note in the aggregate principal amount of HK\$35,000,000 pursuant to the terms of the subscription agreement. All the conditions precedent under the subscription agreement have been fulfilled and completion took place on 31 October 2016. Further details were set out in the Company's announcement dated 31 October 2016.

New loan receivable

Pursuant to the Company's announcement made to the Exchange on 8 November 2016, an unsecured Ioan agreement was entered into between SZ Enterprise Union Finance Limited, an indirect wholly-owned subsidiary of the Company, and the borrower Mr. Wen Qimin on 8 November 2016, according to which a Ioan in a principal amount of HK\$13,000,000 bearing interest at a rate of 10% per annum for a six-month period, was drawn down on 8 November 2016. The final repayment date of the Ioan is on 8 May 2017, but early repayment is allowed. Accrued interest shall be paid in the first instance upon the end of the third month of the term, and thereafter on the final repayment date together with the repayment of the Ioan principal.

17. 報告期後事項

更改公司名稱

本公司之名稱由「長達科技控股有限 公司」更改為「長達健康控股有限公司」,進一步詳情載於本公司日期為 二零一六年十月十八日之公告。

延長應收貸款

於二零一六年十月二十一日,本 集團與借款人訂立延長協議,據 此,金額為6,000,000港元之貸款 之最後還款日期已從二零一六年十 月二十一日延長兩個月至二零一六年十 年十二月二十一日。進一步詳情載 於本公司日期為二零一六年十月 二十一日之公告。

完成認購可換股票據

於二零一六年五月三十一日,本公 司公佈有條件認購事項,根據認 購協議之條款,涉及本金總額為 35,000,000港元之可換股票據。於二 零一六年十月三十一日,認購協議 項下之所有先決條件經已達成且完 成經已落實。進一步詳情載於本公 司日期為二零一六年十月三十一日 之公告。

新應收貸款

根據本公司於二零一六年十一月八 日向聯交所作出之公告,於二零 一六年十一月八日,本公司之間款 全資附屬公司深企聯合小額貸款無 展近利屬公司深企聯合小額貸款無 抵押貸款協議,據此,一筆本金額 為13,000,000港元、按年利率10% 計息及年期六個月之貸款已於二零 一六年十一月八日提取。該筆貸款 一六年十一月八日提取。該筆貸款 一六年十一月八日提取。該筆針利% 之最後還款日期為二零一七年五月 八應首先於年提前還款一條 後還款日期支付。

INDEPENDENT REVIEW REPORT

To the Board of Directors of Prosten Health Holdings Limited (formerly known as Prosten Technology Holdings Limited)

(Incorporated in Cayman Islands with limited liability)

Introduction

We have reviewed the interim financial information set out on pages 3 to 23, which comprises the condensed consolidated statement of financial position of Prosten Health Holdings Limited (formerly known as Prosten Technology Holdings Limited) and its subsidiaries (collectively referred to as the "Group") as at 30 September 2016 and the related condensed consolidated statement of profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-month period then ended, and explanatory notes. The GEM Listing Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of interim financial information to be in compliance with the relevant provisions thereof and Hong Kong Accounting Standard 34 "Interim Financial Reporting" issued by the Hong Kong Institute of Certified Public Accountants. The directors are responsible for the preparation and presentation of the interim financial information in accordance with Hong Kong Accounting Standard 34, "interim financial reporting" issued by the Hong Kong Institute of Certified Public Accountants. Our responsibility is to express a conclusion on the interim financial information based on our review and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

獨立審閲報告

致長達健康控股有限公司 (前稱為長達科技控股有限公司) 董事會 (於開曼群島註冊成立之有限公司)

緒言

我們已審閱載於第3頁至第23頁的中 期財務資料,此等中期財務資料包括 長達健康控股有限公司(前稱為長達 科技控股有限公司)及其附屬公司(統 稱「貴集團」) 於二零一六年九月三十 日的簡明綜合財務狀況表及截至該日 止六個月期間的相關簡明綜合損益及 其他全面收益表、簡明綜合權益變動 表及簡明綜合現金流量表,以及説明 附註。香港聯合交易所有限公司創業 板證券上市規則規定,編製中期財務 資料須符合其相關規定及香港會計師 公會頒佈之香港會計準則第34號「中 期財務報告 |。董事須負責根據香港會 計師公會頒佈之香港會計準則第34號 「中期財務報告」編製及呈列中期財務 資料。我們的責任是根據我們的審閱 對此等中期財務資料作出結論,並按 照雙方協定之委任條款謹向 閣下整 體報告,除此之外本報告別無其他目 的。我們概不會就本報告之內容向任 何其他人士負上或承擔任何責任。

Scope of Review

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants. A review of the interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for Qualified Conclusion

Opening balances and corresponding figures

The consolidated financial statements of the Group for the year ended 31 March 2016, which form the basis for the corresponding figures presented in the current period's interim financial information, and the audit opinion on the consolidated financial statements of the Group for the year ended 31 March 2016 were disclaimer of the possible effect of the limitation on the scope of the audit in relation to the Group's de-consolidated subsidiaries. Details of the disclaimer audit opinion were set out in the independent auditor's report date 27 June 2016 and included in the Company's annual report for the year ended 31 March 2016.

審閲範圍

我們已按照香港會計師公會頒佈之香 港審閱委聘準則第2410號「由實體的 獨立核數師執行之中期財務資料審閲」 進行審閲工作。審閲中期財務資料包 括主要向負責財務及會計事務之人士 作出查詢,以及進行分析及其他審討 程序。審閲範圍遠較根據香港審計準 則進行審核之範圍為小,故不能令我 們可保證我們將知悉在審核中可能發 現之所有重大事項。因此,我們不會 發表審核意見。

保留結論之基準

期初結餘及比較數字

貴集團截至二零一六年三月三十一日 止年度的綜合財務報表形成本期間中 期財務資料的比較數字基準,而由 於 貴集團取消附屬公司綜合入賬, 導致審核範圍限制的可能影響,故此 就 貴集截至二零一六年三月三十一 日止年度的綜合財務報表不發表審核 意見。不發表審核意見的詳情載於日 期為二零一六年六月二十七日的獨立 核數師報告,並已載入 貴公司截至 二零一六年三月三十一日止年度的年 報內。

25

We were not able to obtain sufficient appropriate audit evidence to enable us to assess the limitation of scope for the year ended 31 March 2016. Any adjustment found to be necessary to the opening balances as at 1 April 2016 may affect the balance of accumulated losses as at 1 April 2016, the Group's results and related disclosures in the notes to the interim financial information of the Group for the six months ended 30 September 2016.

Qualified Conclusion

Based on our review, except for the possible effects of the matter described in the basis for qualified conclusion paragraph, nothing has come to our attention that causes us to believe that the interim financial information for the six months ended 30 September 2016 is not prepared, in all material respects, in accordance with Hong Kong Accounting Standard 34, "Interim financial reporting". 我們未能獲得足夠適當審核憑證, 使我們可評估截至二零一六年三月 三十一日止年度的審核範圍限制。如 發現須就於二零一六年四月一日的期 初結餘作任何調整,或會影響到於 二零一六年四月一日的累計虧損結 餘、 貴集團截至二零一六年九月 三十日止六個月的業績及 貴集團中 期財務資料附註內的相關披露資料。

保留結論

按照我們的審閱,除保留結論之基準 一段所述事宜之可能影響外,我們並 無發現任何事項,令我們相信截至二 零一六年九月三十日止六個月的中期 財務資料在各重大方面未有根據香港 會計準則第34號「中期財務報告」編 製。

HLB Hodgson Impey Cheng Limited Certified Public Accountants

Certified Public Accountants

Yu Chi Fat Practising Certificate Number: P05467

Hong Kong, 9 November 2016

國衛會計師事務所有限公司 香港執業會計師

余智發 執業證書編號: P05467

香港,二零一六年十一月九日

INTERIM DIVIDEND

The Board does not recommend the payment of any interim dividend for the six months ended 30 September 2016 (2015: nil).

MANAGEMENT DISCUSSION AND ANALYSIS

Financial Review

Revenue

The effect of the prevailing diversification of the Group's business became more obvious. Comparing with the amount recorded in the corresponding period of last year, the total revenue for the six months ended 30 September 2016 increased by about HK\$3,980,000 to about HK\$8,215,000, to which the revenue contributed from the pharmaceutical and healthcare products business was about 44%, the trading and retailing of jewelry business was about 35% and the lending business was about 21%. Such positive effect of diversification could compensate the negative effect arising from the expiry of contracts with telecommunication operator in the PRC during the year ended 31 March 2016. For the six months ended 30 September 2016, the wireless value-added services ("WVAS") did not generate any revenue.

Cost of sales and gross profit margin

As a result of the increase in the total revenue, the cost of sales increased by about HK\$4,619,000 to about HK\$5,357,000 accordingly for the six months ended 30 September 2016. However, the gross profit dropped by about HK\$639,000 to about HK\$2,858,000 for the six months ended 30 September 2016 in view of the decrease in the scale of WVAS, which was deemed to be a relatively high profit margin business than the other traditional businesses. As such, the overall profit margin decreased from about 83% for the six months ended 30 September 2016 to about 35% for the six months ended 30 September 2016.

中期股息

董事會不建議就截至二零一六年九月 三十日止六個月派發任何中期股息(二 零一五年:無)。

管理層討論及分析

財務回顧

收益

本集團當前業務多元化的效應日益顯 著。與去年同期錄得之金額相比,截 至二零一六年九月三十日止六個月 之總收益增加約3,980,000港元至約 8,215,000港元,其中蔡業及健康護理 產品業務、珠寶買賣及零售業務以及 做益。這一多元化引致之正面效應可 彌補本集團與中國電訊運營商於截至 二零一六年三月三十一日止年度合約 期滿的不利影響。截至二零一六年九 月三十日止六個月,無線增值服務 ([無線增值服務]) 並無產生任何收益。

銷售成本及毛利率

由於總收益增加,截至二零一六年九 月三十日止六個月之銷售成本相應增 加約4,619,000港元至約5,357,000港 元。然而,由於利率視作相對其他傳 統業務較高之無線增值服務規模下 降,故截至二零一六年九月三十日止 六個月之毛利下跌約639,000港元至約 2,858,000港元。因此,整體毛利率由 截至二零一五年九月三十日止六個月 之約83%減少至截至二零一六年九月 三十日止六個月之約35%。

Other income and gains

Other income and gains decreased by about HK\$217,000, from about HK\$412,000 for the six months ended 30 September 2015 to about HK\$195,000 for the six months ended 30 September 2016.

Expenses

Though the business scale of WVAS diminished, the decrease in its operating expenses was offset by the introduction of new businesses of the trading and retailing of jewelry and the lending business in the second half of the year ended 31 March 2016 and the pharmaceutical and healthcare products business in the first quarter of the year ending 31 March 2017. Upon comparing with the amounts for the three months and six months ended 30 September 2015, there was no material change in the total expenses, including selling expenses, administrative expenses and other expenses, for the three months and six months ended 30 September 2016. The total expenses for the three months and six months ended 30 September 2016 was respectively about HK\$6.938.000 and about HK\$12.309.000 while those for the corresponding periods in 2015 were about HK\$5,391,000 and about HK\$12,534,000 respectively.

Loss for the period

The Company incurred a loss of about HK\$9,289,000 for the six months ended 30 September 2016, slightly more than that for the corresponding period in 2015 by about HK\$654,000 upon comparison as a result of the aforesaid reasons.

Total equity

28

Due to the loss attributable to ordinary shareholders of the Company for the six months ended 30 September 2016, the total equity of the Group as at 30 September 2016 was decreased to about HK\$61,006,000.

Liquidity and financial resources

The Group continues to adopt a prudent treasury management policy in order to achieve a better cost control and minimize the cost of fund. The Group's treasury activities are centralized and cash is placed in banks as deposits generally.

其他收入及收益

其他收入及收益由截至二零一五年九 月三十日止六個月之約412,000港元減 少約217,000港元至截至二零一六年九 月三十日止六個月之約195,000港元。

開支

儘管無線增值服務之業務規模縮減, 其經營開支之減少被於截至二零一六 年三月三十一日止年度下半年新增之 珠寶買賣及零售業務以及借貸業務和 於截至二零一七年三月三十一日止年 度第一季度新增的藥業及健康護理產 品業務所抵銷。與截至二零一五年九 月三十日止三個月及六個月之金額相 比,截至二零一六年九月三十日止三 個月及六個月之開支總額(包括銷售 開支、行政開支及其他開支) 並無大 幅變動。截至二零一六年九月三十日 止三個月及六個月之開支總額分別約 為6,938,000港元及約12,309,000港 元,而二零一五年同期則分別約為 5,391,000港元及約12,534,000港元。

期內虧損

鑒於上述理由,本公司於截至二零 一六年九月三十日止六個月產生虧損 約9,289,000港元,與二零一五年同期 相比輕微增加約654,000港元。

權益總額

由於截至二零一六年九月三十日止六 個月的本公司普通股股東應佔虧損, 本集團於二零一六年九月三十日之權 益總額減少至約61,006,000港元。

流動資金及財政資源

本集團繼續採取審慎之財政管理政 策,以便能夠更有效控制成本及盡量 降低資金成本。本集團之財資活動均 為中央管理,而現金一般存放於銀行 作為存款。 As at 30 September 2016, the total amount of cash and cash equivalents was about HK\$15,533,000, dropping from about HK\$28,761,000 as at 31 March 2016. Such decrease in cash and cash equivalents was mainly due to the operating loss of the Group during the six months ended 30 September 2016 and the payment of HK\$5,000,000 related to the acquisition of an investment, which has been completed according to the announcement made on 30 August 2016.

No gearing ratio was presented as at 30 September 2016 and 31 March 2016 as the Group did not have any bank and other borrowing as at 30 September 2016 and 31 March 2016.

Treasury policies and foreign currency exchange exposure

Despite of the fact that the trading transactions, monetary assets and liabilities of the Group are mainly denominated in Renminbi and Hong Kong dollar, it is expected that the impact of the foreign exchange exposure to the Group is immaterial. As such, the Group does not make use of any financial instruments or derivatives to protect itself against the volatility associated with transactions in the ordinary course of business, the existing monetary assets and liabilities denominated in foreign currencies. The majority of the Group's operating assets are located in Mainland China and denominated in Renminbi. However, the Directors will closely monitor the situation and take any necessary and possible measures whenever there is a necessity.

As mentioned above, cash is generally deposited at banks in both the PRC and Hong Kong, and mainly denominated in Renminbi and Hong Kong dollar. As at 30 September 2016, no related hedge was made by the Group (31 March 2016: nil)

Contingent liabilities and capital commitments

As at 30 September 2016, the Group had no material contingent liabilities and capital commitments (31 March 2016: nil).

於二零一六年九月三十日,現金及 現金等值物總額由二零一六年三月 三十一日之約28,761,000港元減少至 約15,533,000港元。現金及現金等值 物之有關減少乃主要由於本集團於截 至二零一六年九月三十日止六個月錄 得經營虧損及有關收購一項投資而支 付5,000,000港元所致。根據於二零 一六年八月三十日作出之公告,有關 收購經已完成。

於二零一六年九月三十日及二零一六 年三月三十一日,並無呈列負債比 率,乃由於本集團於二零一六年九月 三十日及二零一六年三月三十一日並 無任何銀行及其他借貸。

庫務政策及外匯風險

儘管本集團買賣交易、貨幣資產及負 債主要以人民幣及港元為計值單位, 但預期外匯風險對本集團所構成之影 響甚微。因此,本集團並無以任何金 融工具或衍生工具對沖日常業務過程 中之外幣交易、現有外幣資產及負債 所附帶之波動。本集團大部分經營資 產位於中國內地,並以人民幣計值。 然而,董事將密切監督情況,並於有 需要時採取任何必要及可能措施。

如上所述,現金一般存放於中國及香 港的銀行,主要以人民幣及港元為計 算單位。於二零一六年九月三十日, 本集團並無進行相關對沖(二零一六年 三月三十一日:無)。

或然負債及資本承擔

於二零一六年九月三十日,本集團並 無重大或然負債及資本承擔(二零一六 年三月三十一日:無)。

Significant investments, acquisition or disposals

Other than the acquisition of the entire interest in and the shareholders' loans to Sino Yao Shang Technology Limited which was completed and disclosed in the Company's announcement on 30 August 2016, the Group does not have any material investments, acquisition or disposal which requires disclosure during the six months ended 30 September 2016.

Capital structure

The shares of the Company have been listed on GEM since 28 March 2000.

On 31 May 2016, the Company and a potential investor entered into a subscription agreement pursuant to which the subscriber agreed to subscribe for and the Company agreed to issue, a convertible note in the aggregate principal amount of HK\$35 million. This subscription was completed and the relevant announcement was made on 31 October 2016.

As at 30 September 2016, the current ratio and quick ratio of the Group was 1.66 (31 March 2016: 2.34) and 1.31 (31 March 2016: 1.86) respectively.

Save from the above, there has been no material change in the capital structure of the Group during the six months ended 30 September 2016.

Events after the Reporting Period

Extension of loan receivable

Pursuant to the loan agreement made on 22 April 2016 between SZ Enterprise Union Finance Limited, an indirect wholly-owned subsidiary of the Company, and the borrower, Yu Shaoheng, a loan in a principal amount of HK\$6 million bearing interest at a rate of 10% per annum for a six-month period, was granted for an extension on 21 October 2016 for two months from 21 October 2016 to 21 December 2016 after conducting an internal risk assessment on the borrower by the Directors. Save for the extension of the final repayment date of the loan, the teams of the loan agreement have not been modified or

PROSTEN HEALTH HOLDINGS LIMITED Interim Report 2016

重大投資、收購或出售

除已完成並已於本公司日期為二零 一六年八月三十日之公告內披露之收 購中國藥商科技有限公司之全部權益 及股東貸款外,於截至二零一六年九 月三十日止六個月,本集團並無任何 須予披露之重大投資、收購或出售。

資本架構

本 公 司 股 份 已 自 二 零 零 零 年 三 月 二十八日起於創業板上市。

於二零一六年五月三十一日,本公司 與一名潛在投資者訂立認購協議,據 此,認購人同意認購及本公司同意發 行本金總額為35,000,000港元之可換 股票據。該項認購經已完成,且相關 公告已於二零一六年十月三十一日刊 發。

於二零一六年九月三十日,本集團之 流動比率及速動比率分別為1.66(二 零一六年三月三十一日:2.34)及1.31 (二零一六年三月三十一日:1.86)。

除上述者外,本集團之資本架構於截 至二零一六年九月三十日止六個月並 無重大變動。

報告期後事項

延長應收貸款

於二零一六年十月二十一日,董事經 對借款人進行內部風險評估後,批 准將本金額6,000,000港元、按年利 率10%計息及年期六個月之貸款根據 本公司之間接全資附屬公司深企聯合 小額貸款有限公司與借款人余紹享於 二零一六年四月二十二日訂立之貸款 協議,由二零一六年十月二十一日延 長兩個月至二零一六年十二月二十一 日。除延長貸款之最後還款日期外, 貸款協議之條款並無修訂或變動。有 varied. An announcement was made and posted to the website of the Exchange on 21 October 2016 with respect to such extension of Ioan. Interest accrued under this Ioan agreement (prior to the extension) has been fully repaid in October 2016.

Change of Company's name

The name of the Company was changed from "Prosten Technology Holdings Limited" to "Prosten Health Holdings Limited" during the period under review. Further details were set out in the Company's announcement dated 18 October 2016.

Completion of subscription of convertible note

On 31 May 2016, the Company announced the conditional subscription of a convertible note in the aggregate principal amount of HK\$35,000,000 pursuant to the terms of the subscription agreement. All the conditions precedent under the subscription agreement have been fulfilled and completion took place on 31 October 2016. Further details were set out in the Company's announcement dated 31 October 2016.

New loan receivable

Pursuant to the Company's announcement dated 8 November 2016, an unsecured loan agreement was entered into between SZ Enterprise Union Finance Limited, an indirect wholly-owned subsidiary of the Company, and the borrower Mr. Wen Qimin on 8 November 2016, according to which a loan in a principal amount of HK\$13 million bearing interest at a rate of 10% per annum for a six-month period, was drawn down on 8 November 2016. The final repayment date of the loan is on 8 May 2017, but early repayment is allowed. Accrued interest shall be paid in the first instance upon the end of the third month of the term, and thereafter on the final repayment date together with the repayment of the loan principal.

Save from the above, there was no particular event after the reporting period of 30 September 2016.

Employees and Remuneration Policy

As at 30 September 2016, the Group had a total of 36 employees (31 March 2016: 95) and total staff cost for the

關延長貸款之公告已於二零一六年十 月二十一日作出並登載於聯交所網 站。根據該貸款協議應計之利息(延長 之前)已於二零一六年十月悉數償還。

更改公司名稱

於回顧期內,本公司之名稱由「長達科 技控股有限公司」更改為「長達健康控 股有限公司」。進一步詳情載於本公司 日期為二零一六年十月十八日之公告。

完成認購可換股票據

於二零一六年五月三十一日,本公司 公佈有條件認購事項,根據認購協議 之條款,涉及本金總額為35,000,000 港元之可換股票據。於二零一六年十 月三十一日,認購協議項下之所有先 決條件經已達成且完成經已落實。進 一步詳情載於本公司日期為二零一六 年十月三十一日之公告。

應收新貸款

根據本公司日期為二零一六年十一月八日之公告,於二零一六年十一月八日,本公司之間接全資附屬公司深企聯合小額貸款有限公司與借款人溫起 联合小額貸款有限公司與借款人溫起, 一筆本金額為13,000,000港元、按年 利率10%計息及年期六個月之貸款已 於二零一六年十一月八日提取。該筆 貸款之最後還款日期為二零一七年五 月八日,但允許提前還款。應計利息 應首先於年期第三個月末後支付,其 後連同貸款本金之還款一併於最後還 款日期支付。

除上述者外,於二零一六年九月三十 日之報告期後並無特定事項。

僱員及薪酬政策

於二零一六年九月三十日,本集團之 僱員總數為36人(二零一六年三月

> 長達健康控股有限公司 二零一六年中期業績報告

six months ended 30 September 2016 was approximately HK\$4.2 million (six months ended 30 September 2015: HK\$6.1 million). The Group's remuneration policy is basically determined by the performance of individual employees and Directors and the market condition. In addition to salaries and discretionary bonuses, employee benefits included medical schemes, pension contributions, share option schemes and on-job and other training.

Business Review and Outlook

Wireless value-added services

Further to the expiry of WVAS contracts with a PRC telecommunication operator during the year ended 31 March 2016, the Group did not have any revenue from WVAS during the six months ended 30 September 2016. In addition, the Group has set up a PRC company for WVAS to seek for further business opportunities in this industry.

Lending business

The lending business was introduced to the Group in the second half of the year ended 31 March 2016. It continues to grow and gives a positive result to the Group during the six months ended 30 September 2016. The Group will pay a close attention to the market and the external economic environment and consider the possibility of further expansion in the lending business sector.

During the six months ended 30 September 2016, there were two major loans receivables in the principal amount of HK\$13,000,000 each with the Group. One of them had been fully settled together with the accrued interest before 30 September 2016. The other one, which was in the principal amount of HK\$13,000,000 under the loan agreements entered into between SZ Enterprise Union Finance Limited, an indirect wholly-owned subsidiary of the Company and the borrower, Mr. Xu Weiqiang on 31 March 2016 and 20 September 2016 (the "Loan"), was outstanding as at 30 September 2016. The Loan was unsecured and bearing an interest at a rate of 10% per annum for an original

三十一日:95人),而截至二零一六 年九月三十日止六個月之員工成本總 額為約4,200,000港元(截至二零一五 年九月三十日止六個月:6,100,000港 元)。本集團之薪酬政策一般根據個別 僱員及董事之表現及市況釐定。除薪 金及酌情獎金外,僱員福利包括醫療 計劃,退休金供款、購股權計劃及在 職及其他培訓。

業務回顧及展望

無線增值服務

隨着於截至二零一六年三月三十一日 止年度與中國電信運營商訂立之無線 增值服務合約期滿後,本集團於截至 二零一六年九月三十日止六個月並無 來自無線增值服務之任何收益。此 外,本集團已成立一間從事無線增值 服務之中國公司以於該行業尋求進一 步商機。

借貸業務

本集團於截至二零一六年三月三十一 日止年度下半年開始從事借貸業務。 截至二零一六年九月三十日止六個 月,該業務持續增長,為本集團業績 帶來正面貢獻。本集團將密切監察市 場及外部經濟環境,物色進一步擴張 借貸業務的機會。

截至二零一六年九月三十日止六個 月,本集團擁有兩筆主要應收貸款, 本金額各自為13,000,000港元。其中 一筆已於二零一六年九月三十日之前 連同應計利息悉數償還。而另一筆由 本公司之間接全資附屬公司深企聯合 小額貸款有限公司與借款人許偉強先 生於二零一六年三月三十一日及二零 一六年九月二十日訂立之貸款協議下 本金額為13,000,000港元的貸款(「貸 款)於二零一六年九月三十日尚未償 還。貸款為無抵押,按年利率10%計

PROSTEN HEALTH HOLDINGS LIMITED Interim Report 2016 term of six months and an extended term of another six months . The original and extended final repayment date is 21 September 2016 and 21 March 2017 respectively and early repayment is allowed. Interest accrued under the Loan for the original term has been fully paid to the Group before 30 September 2016. Accrued interest for the extended term shall be paid in the first instance upon the end of the third month of the extended term, and thereafter on the final repayment date together with repayment of the principal. The Loan constitutes transaction carried out as part of the ordinary and usual course of business of the Group and will continue to bring in interest income to the Group. The Loan was granted to enhance the borrower's short-term cash flow. For more details of the Loan, please refer to the Company's announcements dated 21 March 2016 and 20 September 2016.

Trading and Retailing of Jewelry Business

The trading and retailing of jewelry business was also introduced to the Group in the second half of the year ended 31 March 2016 by acquiring a group of jewelry companies which are mainly located in the PRC. Such acquisition was to broaden the income sources of the Group. The Group incurred loss in this business segment due to the maintenance of the selling and administrative expenses in the PRC.

Pharmaceutical and Healthcare Products Business

Further to the commencement of pharmaceutical and healthcare products business in the first quarter of the year ending 31 March 2017 and the completion of the acquisition of the entire interest in and shareholder's loans to Sino Yao Shang Technology Limited, the announcement of which was made to the website of the Exchange on 30 August 2016, the Group is expected to benefit from the enormous population of 1.4 billion in the PRC. In view of the current challenging economic conditions in the PRC, the Directors expect that it could turn out to be a good business opportunity for the Group to develop a sound market there. As the Group has just made effort in developing this business segment, the pharmaceutical and healthcare products business is still at a developing stage.

息,原始年期為六個月,並另行延長 六個月。原始及延長之最後還款日期 分別為二零一六年九月二十一日及二 零一七年三月二十一日,允許提前還 款。貸款於原始年期的應計利息已於 二零一六年九月三十日之前悉數支付 予本集團。延長年期的應計利息應首 先於延長年期第三個月末後支付,其 後連同本金之還款一併於最後還款日 期支付。貸款構成於本集團一般及日 常業務過程中進行的交易,並將繼續 為本集團帶來利息收入。貸款旨在提 升借款人的短期現金流量。有關貸款 的更多詳情,請參閱本公司日期為二 零一六年三月二十一日及二零一六年 九月二十日之公告。

珠寶買賣及零售業務

截至二零一六年三月三十一日止年度 下半年,本集團亦透過收購一系列主 要位於中國之珠寶公司開始從事珠寶 買賣及零售業務。有關收購旨在擴大 本集團之收入來源。為維持於中國的 銷售及行政開支,本集團於該業務分 部產生虧損。

藥業及健康護理產品業務

隨著截至二零一七年三月三十一日止 年度第一季度蔡業及健康護理產品業 務的開展,以及收購中國藥商科技有 限公司之全部權益及股東貸款(有關公 告已於二零一六年八月三十日刊載於 聯交所網站)的完成,預期本集團將受 益於中國14億之龐大人口。鑒於當前 中國經濟狀況充滿挑戰,董事預期此 舉或為本集團開發市場之良機。由於 本集團剛開始發展該業務分部,故 蔡業及健康護理產品業務尚處於發展 階段。 Nevertheless, the Group would continue to take a cautious approach to balance between the business development process and its financial liquidity position.

Updates on matters relating to the De-consolidation

With reference to the annual report of the Company for the year ended 31 March 2016 ("2016 Annual Report"), the Directors considered that the Group was unable to govern the De-Consolidated Subsidiaries (as defined under the 2016 Annual Report) and the control over the De-Consolidated Subsidiaries was lost. Therefore, from 1 January 2016 onwards, the Group had de-consolidated the De-Consolidated Subsidiaries from its financial statements for the financial year ended 31 March 2016 and thereafter (the "De-Consolidation").

The Company has been in negotiation with the relevant party(ies) with an aim to resolving the matters arising from or in connection with the loss of control over the De-Consolidated Subsidiaries.

The Company has also engaged an internal control reviewer to conduct an internal control review on the Group with the following objectives:

- to review and assess whether there is any existing internal control weakness of the Group indicated by the incident(s) leading to the De-consolidation;
- (b) to review the Group's current enterprise risk management and internal controls in order to assist the Directors to ensure that the management of the Group maintains a sound system for (i) evaluating the risks it is willing to take in achieving the Group's strategic objectives; and (ii) ensuring the internal controls to safeguard the investments of the shareholders of the Company (the "Shareholders") and the Group's assets; and
- (c) to make recommendation on any measures which, in the internal control reviewer's opinion, the Group should take in order to rectify any material weakness which has been identified in (a) above and its enterprise risk management and internal controls.

儘管如此,本集團將繼續採取審慎方 法以平衡業務發展進程與其流動資金 狀況。

有關取消綜合入賬事宜之最新資料

經參考本公司截至二零一六年三月 三十一日止年度之年度報告(「二零 一六年年報」),董事認為本集團無法 管理該等取消綜合入賬附屬公司(定 義見二零一六年年報),並失去對該等 取消綜合入賬附屬公司之控制權。因 此,自二零一六年一月一日起,本集 團已將該等取消綜合入賬附屬公司終 止於其截至二零一六年三月三十一日 止財政年度及其後之財務報表內綜合 入賬(「取消綜合入賬」)。

本公司一直與有關方進行磋商, 旨在 解決因失去對該等取消綜合入賬附屬 公司之控制權而產生或與之相關之事 宜。

本公司亦已聘請一家內部監控審閱顧 問,以對本集團進行內部控制檢討, 旨在:

- (a) 審閲及評估導致取消綜合入賬 之事件是否表明本集團內部控 制存在任何現有缺陷:
- (b) 審閱本集團之當前企業風險管 理及內部控制,以協助董事確 保本集團之管理維持健全之系 統,以(i)評估本集團為達致其 策略目標將承擔之風險;及(ii) 確保內部控制保護本公司股東 (「股東」)投資及本集團資產; 及
- (c) 就內部監控審閱顧問認為本集 團為修正於上文(a)中已識別及 其企業風險管理及內部控制之 任何重大缺陷應採取之任何措 施提供建議。

PROSTEN HEALTH HOLDINGS LIMITED Interim Report 2016

The scope of review shall cover four major areas, namely, (i) corporate internal control; (ii) financial reporting and disclosure internal control; (iii) internal control over business processes; and (iv) operational manual. The aforesaid internal control review has been commenced.

The Company will keep the Shareholders and potential investors of the Company informed of any material development in the above matters as and when appropriate.

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at 30 September 2016, the interests and short positions of the Directors and chief executive in the shares and underlying shares of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) which were notified to the Company and the Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO), or which were recorded in the register required to be kept by the Company under Section 352 of the SFO, or which were, pursuant to the code of conduct regarding securities transactions by Directors adopted by the Company, notified to the Company and the Exchange, were as follows: 審閱範圍涵蓋四個主要方面,即:(i) 企業內部控制:(ii)財務報告與內部控 制披露:(iii)業務流程之內部控制;及 (V)營運手冊。上述內部監控檢討已開 始進行。

本公司將在適當時候就任何與上述事 宜有關之重大發展通知本公司股東及 潛在投資者。

董事及主要行政人員於股份及相關 股份之權益及淡倉

於二零一六年九月三十日,董事及主 要行政人員於本公司或其任何相聯法 團(定義見證券及期貨條例(「證券及 期貨條例」)第XV部)之股份及相關股 份中,擁有根據證券及期貨條例第XV 部第7及第8分部須知會本公司及聯交 所之權益及淡倉(包括根據證券及期貨 條例相關條文彼等被當作或視為擁有 之權益或淡倉),或須記錄於本公司根 據證券及期貨條例第352條須備存之登 記冊內之權益及淡倉,或根據本公司 所採納有關董事進行證券交易之行為 守則須知會本公司及聯交所之權益及 淡倉如下:

Long positions in the ordinary shares of the Company

於本公司普通股之好倉

Name of Director 董事姓名	Notes 附註	Capacity and nature of interest 身份及 權益性質	Number of ordinary shares 普通股數目	Percentage of the Company's issued share capital 佔本公司 已發行股本 百分比 Note (3) 附註(3)
Mr. Yip Heon Keung 葉向強先生	(1)	Personal Interest 個人權益	6,300,000	0.58%
Mr. Chen Weixi 陳煒熙先生	(2)	Interest of a controlled corporation 一間受控制公司之權益	294,276,619	26.87%
Mr. Song Xuxi 宋旭曦先生	(3)	Personal Interest 個人權益	1,000,000	0.09%

Notes:

- Mr. Yip Heon Keung is personally interested in 6,300,000 shares of the Company.
- (2) 294,276,619 shares of the Company are held by Dynamic Peak Limited and its issued share capital is held as to 80% by Mr. Chen Weixi and as to the remaining 20% by Mr. Xu Zhigang, both of them are Directors. By virtue of the SFO, Mr. Chen Weixi is deemed to be interested in 294,276,619 shares of the Company held by Dynamic Peak Limited.
- (3) Mr. Song Xuxi is personally interested in 1,000,000 shares of the Company.
- (4) Based on 1,095,360,500 shares of the Company in issue as at 30 September 2016.

Long positions in underlying shares of the Company

Share Options

The Company adopts and administers a share option scheme which is currently in force and effect for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group's operations. The Company's original share option scheme was approved by the Company's Shareholders on 7 March 2000, and was terminated and replaced by a share option scheme approved by the Shareholders on 9 April 2002, which in turn was terminated and replaced by a new share option scheme approved by the Shareholders on 5 August 2011 (the "2011 Scheme").

A summary of the share option schemes is set out below:

2011 Scheme

At the annual general meeting of the Company held on 5 August 2011 (the "2011 AGM"), an ordinary resolution was passed by the Shareholders to approve and adopt the 2011 Scheme. 附註:

- (1) 葉 向 強 先 生 個 人 擁 有 本 公 司 6,300,000 股股份之權益。
- (2) Dynamic Peak Limited持有294,276,619 股本公司股份及其已發行股本由陳 煒熙先生持有80%及由徐志剛先生 持有餘下20%(二人均為董事)。根 據證券及期貨條例,陳煒熙先生被 視為於Dynamic Peak Limited 持有之 294,276,619股本公司股份中擁有權 益。
 - 宋 旭 曦 先 生 個 人 擁 有 本 公 司 1,000,000股股份之權益。
- (4) 根據於二零一六年九月三十日已發 行之1,095,360,500股本公司股份計 算。

於本公司相關股份之好倉

購股權

(3)

本公司採納及管理一項目前有效及具 效力之購股權計劃,旨在鼓勵及獎勵 對本集團之成功經營作出貢獻之合資 格參與者。本公司股東於二零零年 三月七日批准之本公司原有購股權計 劃已終止,並被股東於二零零二年四 月九日批准之一項購股權計劃取代, 而該計劃已終止及被股東於二零一一 年八月五日批准之一項新購股權計劃 (「二零一一年計劃」)取代。

購股權計劃之概要載列如下:

二零一一年計劃

在本公司於二零一一年八月五日舉行 之股東週年大會(「二零一一年股東週 年大會」)上,股東通過一項普通決議 案,批准及採納二零一一年計劃。 The 2011 Scheme became effective for a period of 10 years commencing on 10 August 2011. Eligible participants of the 2011 Scheme include all Directors and employees of the Group, suppliers, customers, consultants who provided services to the Group, shareholders of the subsidiaries of the Group and joint venture partners. Under the 2011 Scheme, the Directors may, at their sole discretion, grant to any eligible participants options to subscribe for ordinary shares of the Company at the highest of (i) the closing price of shares of the Company on GEM as stated in the Exchange's daily quotation sheet on the date of the offer of grant; (ii) the average closing price of the shares of the Company on GEM as stated in the Exchange's daily quotation sheets for the five trading days immediately preceding the date of the offer of grant; and (iii) the nominal value of the Company's share. The offer of a grant of options may be accepted within 21 days from the date of the offer. A nominal consideration of HK\$1 is payable on acceptance of the grant of an option. The exercise period of the options granted is determinable by the Directors, which commences after the date of offer with a certain vesting period and ends in any event not later than 10 years from the respective date when the share options are granted, subject to the provisions for early termination thereof.

An ordinary resolution was passed at the annual general meeting of the Company on 28 September 2016 (the "2016 AGM") to refresh the scheme mandate limit of the 2011 Scheme. The total number of shares of the Company which may be allotted and issued upon exercise of all options to be granted under the 2011 Scheme is an amount equivalent to 10% of the shares of the Company in issue as at the date of the 2016 AGM.

The maximum number of shares of the Company to be allotted and issued upon the exercise of all outstanding options granted and yet to be exercised under the 2011 Scheme and any other share option schemes of the Group must not in aggregate exceed 30% of the relevant class of shares of the Company in issue from time to time.


二零一一年計劃自二零一一年八月十 日開始生效,為期十年。二零一一年 計劃之合資格參與者包括本集團所有 董事及僱員、供應商、客戶、為本集 團提供服務之顧問、本集團附屬公司 之股東及合營企業夥伴。根據二零 一一年計劃,董事可全權酌情決定向 任何合資格參與者授出購股權,以按 (i)於要約授出日期聯交所每日報價表 上所列本公司股份在創業板之收市價; (ii)緊接要約授出日期前五個交易日聯 交所每日報價表上所列本公司股份在 創業板之平均收市價;及(iii)本公司股 份面值之價格(以最高者為準)認購本 公司之普通股。接納授出購股權要約 之期限為要約日期起計二十一日內。 接納授出購股權時須支付象徵式代價1 港元。所授出購股權之行使期限由董 事釐定,於要約日期後開始,附有若 干歸屬期,及在任何情況下最遲須於 授出購股權之各相關日期起計十年屆 滿,惟須受提前終止之條文所規限。

本公司於二零一六年九月二十八日舉 行之股東週年大會(「二零一六年股東 週年大會」)上通過一項普通決議案, 以更新二零一一年購股權計劃之計劃 授權限額。於行使根據二零一一年計 劃將授出之所有購股權時可配發及發 行之本公司股份總數,其數目相等於 截至二零一六年股東週年大會舉行日 期之本公司已發行股份之10%。

於行使根據二零一一年計劃及本集團 之任何其他購股權計劃所授出及仍未 行使之所有尚未獲行使之購股權時將 予配發及發行之本公司股份最高數 目,合共不得超過不時已發行之本公 司有關類別股份之30%。 The number of shares in respect of which options may be granted to any individual in any 12-month period is not permitted to exceed 1% of the shares of the Company in issue at any point in time, without prior approval from the Shareholders. Options granted to substantial Shareholders or independent non-executive Directors in excess of 0.1% of the Company's share capital and with an aggregate value in excess of HK\$5 million must be approved in advance by the Shareholders. The 2011 Scheme does not provide for any minimum period for holding of options or any performance target before exercise of options.

The following Director was granted share options under the 2011 Scheme to subscribe for shares of the Company, details of which are as follows: 於任何十二個月期間可授予任何個人 之購股權所涉之股份數目,在未獲股 東事先批准前,不得超逾本公司於任 何時間已發行股份之1%。授予主要 股東或獨立非執行董事之購股權倘 超逾本公司股本之0.1%及總價值逾 5,000,000港元,必須事先獲股東批 准。二零一一年計劃並無規定任何持 有購股權之最短期限或行使購股權前 之任何表現目標。

以下董事根據二零一一年計劃獲授購 股權以認購本公司股份,詳情如下:



PROSTEN HEALTH HOLDINGS LIMITED Interim Report 2016 Save as disclosed above, as at 30 September 2016, none of the Directors and chief executive of the Company had an interest or short position in the ordinary shares or underlying shares of the Company or any of its associated corporations that was notified to the Company and the Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO, or was required to be recorded pursuant to Section 352 of the SFO, or as otherwise notified to the Company and the Exchange pursuant to Rule 5.46 of the GEM Listing Rules.

INTERESTS AND SHORT POSITIONS OF SUBSTANTIAL SHAREHOLDERS

As at 30 September 2016, shareholders (other than the Directors or chief executive of the Company) who had interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO were as follows:

除上文所披露者外,於二零一六年九 月三十日,本公司董事及主要行政人 員於本公司或其任何相聯法團之普通 股或相關股份中概無擁有根據證券及 期貨條例第XV部第7及第8分部須知 會本公司及聯交所之權益或淡倉,或 根據證券及期貨條例第352條須予記 錄,或根據創業板上市規則第5.46條 須知會本公司及聯交所之權益或淡倉。

主要股東之權益及淡倉

於二零一六年九月三十日,於本公司 股份或相關股份中擁有根據證券及期 貨條例第XV部第2及第3分部之條文 須向本公司披露,或須記錄於本公司 根據證券及期貨條例第336條須備存之 登記冊之權益或淡倉之股東(本公司董 事或主要行政人員除外)如下:

Long positions in the ordinary shares of the Company

於本公司普通股之好倉

			Per	centage of the
			Con	npany's issued
		Capacity and		share capital
Name of		nature of interest	Number of	佔本公司
Shareholder	Notes	身份及	ordinary shares	已發行股本
股東名稱	附註	權益性質	普通股數目	百分比
				Note (6)
				附註(6)
Dynamic Peak Limited	(1)	Beneficially owned	294,276,619	26.87%
		實益擁有		
Right Advance Management	t (2)	Beneficially owned	111,000,000	10.13%
Limited		實益擁有		
Ma Mang Li Mai	(0)	Internet of a controlled	111 000 000	10 100/
Ms. Wang Li Mei	(2)	Interest of a controlled	111,000,000	10.13%
王立梅女士		corporation 問题 (中国) 二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十		
		一間受控制公司之權益		

Name of Shareholder 股東名稱	Notes 附註	Capacity and nature of interest 身份及 權益性質	Number of ordinary shares 普通股數目	Percentage of the Company's issued share capital 佔本公司 已發行股本 百分比 Note (6) 附註(6)
Mr. Wang Leilei 王雷雷先生	(2)	Interest of a controlled corporation 一間受控制公司之權益	111,000,000	10.13%
Rainbow Enterprise Holdings Co., Limited	(3)	Beneficially owned 實益擁有	100,847,000	9.21%
Mr. Cheng Haiqing 程海慶先生	(3)	Interest of a controlled corporation 一間受控制公司之權益	100,847,000	9.21%
Will City Limited 志城有限公司	(4)	Beneficially owned 實益擁有	100,000,000	9.13%
Ms. Zhang Yingnan 張穎楠女士	(4)	Interest of a controlled corporation 一間受控制公司之權益	100,000,000	9.13%
Mr. Pei Chuang 裴創先生		Beneficially owned 實益擁有	70,000,000	6.39%
South Pearl Group Limited	(4)	Beneficially owned 實益擁有	64,500,000	5.89%
Mr. Song Weiliang 宋偉亮先生	(4)	Interest of a controlled corporation 一間受控制公司之權益	64,500,000	5.89%
Notes:			附註:	
British Virgin Island	s and its iss Veixi and as	company incorporated in the sued share capital is held as to s to the remaining 20% by Mr. Directors.	處女群島註 行股本由陳	ak Limited為一間於英屬 冊成立之公司,其已發 煒熙先生持有80%及由 持有餘下20%。兩位均為

董事。

- (2) Right Advance Management Limited ("Right Advance") is a company incorporated in the British Virgin Islands and its entire issued share capital is registered in the name of Ms. Wang Li Mei, and such shares are ultimately owned by Mr. Wang Leilei. Ms. Wang Li Mei is the sole director of Right Advance.
- (3) Rainbow Enterprise Holdings Co., Limited is a company incorporated in the British Virgin Islands and its entire issued share capital is held by Mr. Cheng Haiqing.
- (4) Will City Limited is a company incorporated in the British Virgin Islands and its entire issued share capital is held by Ms. Zhang Yingnan.
- (5) South Pearl Group Limited is a company incorporated in the British Virgin Islands and its entire issued share capital is held by Mr. Song Weiliang.
- (6) Based on 1,095,360,500 shares of the Company in issue as at 30 September 2016.

Save as disclosed above, as at 30 September 2016, the Company has not been notified by any persons (other than the Directors or chief executive of the Company) who had interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO.

COMPETING INTERESTS

None of the Directors or the controlling shareholders of the Company or their respective associates (as defined under the GEM Listing Rules) have any interests in a business which competes or may compete with the business of the Group, or has any other conflict of interest with the Group during the period under review.

- (2) Right Advance Management Limited (「Right Advance」)為一間於英屬 處女群島註冊成立之公司,其全部 已發行股本以王立梅女士之名義註 冊,而王雷雷先生則最終擁有該等 股份。王立梅女士為Right Advance 之唯一董事。
- (3) Rainbow Enterprise Holdings Co., Limited為一間於英屬處女群島註冊 成立之公司,其全部已發行股本由 程海慶先生持有。
- (4) 志城有限公司為一間於英屬處女群 島註冊成立之公司,其全部已發行 股本由張潁楠女士持有。
- (5) South Pearl Group Limited為一間於 英屬處女群島註冊成立之公司,其 全部已發行股本由宋偉亮先生持有。
- (6) 根據於二零一六年九月三十日已發 行之1,095,360,500股本公司股份計 算。

除上文披露者外,於二零一六年九月 三十日,本公司並無獲任何人士(董事 或本公司主要行政人員除外)知會彼等 於本公司股份或相關股份中擁有根據 證券及期貨條例第XV部第2及第3分 部之條文須向本公司披露的權益或淡 倉,或須記錄於本公司根據證券及期 貨條例第336條須備存之登記冊內之權 益或淡倉。

競爭權益

於回顧期內,各董事或本公司之控股 股東或彼等各自之聯繫人(定義見創業 板上市規則)於與本集團業務構成競爭 或可能構成競爭或與本集團有任何其 他利益衝突之業務中,概無擁有任何 權益。

PURCHASE, REDEMPTION OR SALE OF THE COMPANY'S LISTED SECURITIES

During the six months ended 30 September 2016, neither the Company nor any of its subsidiaries has purchased, redeemed or sold any of the Company's listed securities.

DIRECTORS' SECURITIES TRANSACTIONS

The Company has adopted a code of conduct regarding securities transactions by Directors on terms no less exacting than the required standard of dealings as set out in Rules 5.48 to 5.67 of the GEM Listing Rules. In response to specific enquiry made by the Company, each of the Directors gave confirmation that he/she complied with the required standard of dealings and the code of conduct regarding securities transactions by the Directors throughout the six months ended 30 September 2016.

CORPORATE GOVERNANCE CODE

Save as the deviation disclosed below, the Company has complied with all the code provisions set out in the Corporate Governance Code (the "CG Code") as contained in Appendix 15 to the GEM Listing Rules throughout the period under review.

With respect to the deviation, the CG Code provision A.2.1 provides that the roles of the chairman and chief executive officer ("CEO") should be separated and should not be performed by the same individual. The division of responsibilities between the chairman and CEO should be clearly established and set out in writing. During the period under review, the Company has not appointed a CEO and the Chairman, Mr. Xu Zhigang, assumed the post of acting CEO. The Board considers that the current arrangement is adequate in view of the size and complexity of the Group's operations. The Board will, nonetheless, review the business growth of the Group and locate suitable candidate to fill the vacancy of the CEO when considered essential and will continue setting out a clear division of responsibilities at the board level and the day-to-day management team to ensure a proper balance of power and authority within the Company.

購買、贖回或出售本公司之上市證 券

於截至二零一六年九月三十日止六個 月內,本公司或其任何附屬公司概無 購買、贖回或出售本公司任何上市證 券。

董事進行之證券交易

本公司已採納一套有關董事進行證券 交易之行為守則,其條款之嚴格程度 不遜於創業板上市規則第5.48條至5.67 條所載之交易必守標準。經本公司作 出特定查詢後,各董事均確認,其於 截至二零一六年九月三十日止六個月 整段期間,一直遵守交易必守標準及 董事進行證券交易之行為守則。

企業管治守則

除以下披露之偏離外,於回顧期內, 本公司一直遵守創業板上市規則附錄 十五所載之企業管治守則(「企業管治 守則」)之所有守則條文。

Code provision A.6.7 of the CG Code requires all independent non-executive directors and non-executive directors should attend general meetings of listed issuers. Mr. Poon Yan Wai and Mr. Xu Xiaoping, being independent non-executive Directors, and Mr. Chen Weixi, Mr. Yip Heon Keung and Mr. Song Xuxi, being non-executive Directors, were unable to attend the annual general meeting held on 28 September 2016 due to their personal commitments.

CHANGE OF DIRECTORS' INFORMATION

Mr. Lam Kwok Cheong, an independent non-executive Director of the Company, has resigned as non-executive director of Mega Medical Technology Limited (stock code: 876) and resigned as independent non-executive director of Southwest Securities International Securities Limited (stock code: 812), both of which are companies with shares listed on the Exchange, effective from 1 July 2016 and 19 September 2016 respectively.

Save as disclosed above, there is no change in director's information to be disclosed.

AUDIT COMMITTEE

The Company established the Audit Committee on 7 March 2000 and has formulated and from time to time amended its written terms of reference in accordance with the provisions set out in the CG Code. The primary duties of the Audit Committee include review and supervision of the Group's financial reporting system, risk management and internal control procedures, review of the Group's financial information and review of the Group's relationship with its auditors.

As at the date of this report, the Audit Committee comprised three independent non-executive Directors, namely Mr. Poon Yan Wai (Chairman of the Audit Committee), Mr. Xu Xiaoping and Mr. Lam Kwok Cheong and one non-executive Director, Mr. Chen Weixi.

The Audit Committee has reviewed this report and has provided advice and comments thereon.

企業管治守則之守則條文第A.6.7條規 定,所有獨立非執行董事及非執行董 事應出席上市發行人的股東大會。獨 立非執行董事潘仁偉先生及徐小平先 生,非執行董事陳煒熙先生、葉向強 先生及宋旭曦先生因個人需要未能出 席於二零一六年九月二十八日舉行的 股東週年大會。

董事資料變更

本公司之獨立非執行董事林國昌先生 已辭任美加醫學科技有限公司(股份代 號:876)之非執行董事及西證國際證 券股份有限公司(股份代號:812)之 獨立非執行董事(此兩間公司均為聯交 所上市公司),分別由二零一六年七月 一日及二零一六年九月十九日起生效。

除上文披露者外,概無其他需披露之 董事資料變更。

審核委員會

本公司已於二零零零年三月七日成立 審核委員會,並已根據企業管治守則 之條文制訂及不時修訂其書面職權範 圍。審核委員會之主要職責包括審閱 及監察本集團之財務申報制度、風險 管理及內部控制程序、審閱本集團之 財務資料,及檢討本集團與其核數師 之關係。

於本報告日期,審核委員會由三名獨 立非執行董事潘仁偉先生(審核委員會 主席)、徐小平先生及林國昌先生以及 一名非執行董事陳煒熙先生組成。

審核委員會已審閱本報告,並就此提 供意見及評論。

REMUNERATION COMMITTEE

In accordance with the CG Code, the Company established the remuneration committee ("Remuneration Committee") on 17 June 2005 with written terms of reference. The principal responsibilities of the Remuneration Committee include making recommendations to the Board on the Company's policy and structure for remuneration of all Directors and senior management and reviewing the specific remuneration packages of all executive Directors and senior management by reference to corporate goals and objectives resolved by the Board from time to time.

The Remuneration Committee comprises two independent non-executive Directors, namely Mr. Xu Xiaoping (Chairman of the Remuneration Committee) and Mr. Lam Kwok Cheong, and one executive Director, Mr. Xu Zhigang.

NOMINATION COMMITTEE

In accordance with the CG Code, the Company established the nomination committee ("Nomination Committee") on 29 March 2012 with written terms of reference. The principal responsibilities of the Nomination Committee include formulating nomination policy and making recommendations to the Board on nomination and appointment of Directors and Board succession, developing selection procedures for nomination of candidates, reviewing the size, structure and composition of the Board, as well as assessing the independence of independent nonexecutive Directors.

The Nomination Committee comprises one executive Director, namely Mr. Xu Zhigang (Chairman of the Nomination Committee) and two independent nonexecutive Directors, Mr. Xu Xiaoping and Mr. Lam Kwok Cheong.

By Order of the Board **Xu Zhigang** *Chairman*

Hong Kong, 9 November 2016

PROSTEN HEALTH HOLDINGS LIMITED Interim Report 2016

薪酬委員會

根據企業管治守則之規定,本公司已 於二零零五年六月十七日成立薪酬委 員會(「薪酬委員會」),並制定其書面 職權範圍。薪酬委員會之主要職責包 括就本公司所有董事及高級管理層之 薪酬政策及架構向董事會提供建議, 以及經參考董事會不時議決之企業目 標及目的後,審閲所有執行董事及高 級管理層之特定薪酬待遇。

薪酬委員會由兩名獨立非執行董事徐 小平先生(薪酬委員會主席)及林國昌 先生,以及一名執行董事徐志剛先生 組成。

提名委員會

根據企業管治守則之規定,本公司已 於二零一二年三月二十九日成立提名 委員會(「提名委員會」),並制定其 書面職權範圍。提名委員會之主要職 責為制定提名政策,以及就董事之提 名及委任和董事會接任之安排向董事 會提出建議、制訂提名候選人的遴選 程序、檢討董事會之規模、架構及組 成,以及評估獨立非執行董事之獨立 性。

提名委員會由一名執行董事徐志剛先 生(提名委員會主席)及兩名獨立非執 行董事徐小平先生及林國昌先生組成。

承董事會命 *主席* **徐志剛**

香港,二零一六年十一月九日

PROSTEN

PROSTEN HEALTH HOLDINGS LIMITED

Unit 905, 9/F, Star House 3 Salisbury Road Tsim Sha Tsui, Kowloon Hong Kong

長達健康控股有限公司

香港九龍尖沙咀梳士巴利道 3 號 星光行 9 樓 905 室

www.prosten.com